Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome

IMPORTANCE: In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Neurol
Hauptverfasser: Orlova, Yulia, Rizzoli, Paul, Loder, Elizabeth
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2018
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885255/
https://ncbi.nlm.nih.gov/pubmed/29482205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.5144
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge